Zacks Research Issues Pessimistic Outlook for CRL Earnings

Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) - Equities research analysts at Zacks Research reduced their Q3 2025 earnings per share (EPS) estimates for Charles River Laboratories International in a research note issued to investors on Wednesday, May 28th. Zacks Research analyst R. Department now anticipates that the medical research company will earn $2.37 per share for the quarter, down from their previous forecast of $2.40. The consensus estimate for Charles River Laboratories International's current full-year earnings is $9.36 per share. Zacks Research also issued estimates for Charles River Laboratories International's Q4 2025 earnings at $2.36 EPS, Q3 2026 earnings at $2.51 EPS and Q4 2026 earnings at $2.48 EPS.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, topping the consensus estimate of $2.06 by $0.28. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $984.17 million during the quarter, compared to the consensus estimate of $942.34 million. During the same quarter last year, the firm posted $2.27 EPS. The company's quarterly revenue was down 2.7% on a year-over-year basis.

CRL has been the subject of several other reports. Evercore ISI raised Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 target price for the company in a research report on Thursday, May 8th. Citigroup upgraded shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and increased their target price for the stock from $155.00 to $175.00 in a research report on Tuesday, March 4th. Redburn Atlantic upgraded shares of Charles River Laboratories International from a "neutral" rating to a "buy" rating and cut their target price for the stock from $188.00 to $182.00 in a research report on Friday, May 23rd. Mizuho cut their target price on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a research report on Wednesday, April 9th. Finally, Cowen upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating in a research report on Wednesday, May 14th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $171.85.

Charles River Laboratories International Stock Down 1.6%

NYSE:CRL traded down $2.19 during trading hours on Friday, hitting $135.51. 804,389 shares of the company traded hands, compared to its average volume of 996,378. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. The firm's 50-day simple moving average is $129.03 and its 200-day simple moving average is $160.44. Charles River Laboratories International has a one year low of $91.86 and a one year high of $254.15. The company has a market cap of $6.66 billion, a PE ratio of 903.40, a PEG ratio of 4.54 and a beta of 1.50.

Institutional Investors Weigh In On Charles River Laboratories International

Several institutional investors have recently added to or reduced their stakes in CRL. Allspring Global Investments Holdings LLC lifted its holdings in shares of Charles River Laboratories International by 2.7% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock worth $330,231,000 after purchasing an additional 47,221 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Charles River Laboratories International by 46.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,301 shares of the medical research company's stock worth $987,000 after purchasing an additional 1,679 shares during the period. Boston Trust Walden Corp lifted its holdings in shares of Charles River Laboratories International by 4.3% during the fourth quarter. Boston Trust Walden Corp now owns 204,483 shares of the medical research company's stock worth $37,748,000 after purchasing an additional 8,338 shares during the period. E. Ohman J or Asset Management AB lifted its holdings in shares of Charles River Laboratories International by 225.0% during the fourth quarter. E. Ohman J or Asset Management AB now owns 2,600 shares of the medical research company's stock worth $480,000 after purchasing an additional 1,800 shares during the period. Finally, Smartleaf Asset Management LLC raised its position in Charles River Laboratories International by 61.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 459 shares of the medical research company's stock valued at $84,000 after acquiring an additional 175 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company's stock.

Insider Activity

In related news, EVP Joseph W. Laplume sold 500 shares of the firm's stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total transaction of $72,705.00. Following the sale, the executive vice president now owns 19,513 shares of the company's stock, valued at $2,837,385.33. This trade represents a 2.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 1.30% of the company's stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).